Daré Bioscience
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Reproductive/Sexual Health
Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Daré was founded to change that. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions.
Company HQ City:
san diego
Company HQ State:
california
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
products for contraception to menopause, sexual health to vaginal health and HPV: FDA approved, XACIATO; commercializing summer 2026, DARE to PLAY and DARE to RESTORE; in Phase 3, Ovaprene; in Phase 2, DARE-HPV; in Phase 1, Casea S; preclinical, DARE-LARC1 and DARE-NHC
CEO
Sabrina Johnson
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
8
Exchange
Nasdaq
Ticker
DARE
When you expect your next catalyst update?
June 2026
What is your next catalyst (value inflection) update?
Revenue commencing summer 2026, Phase 3 data 2027, Phase 2 data 2027
Primary Speaker



